CCCameron Chalker

Cameron Chalker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cameron Chalker has a total of 43 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra O. Sokolova

    Department of Medical Oncology, Oregon Health & Science University (OHSU), Portland, USA

    2 shared publications
  • Brittany Barber

    Department of Otolaryngology Head and Neck Surgery and University of Washington, Seattle, Washington, USA

    2 shared publications
  • Christina S. Baik

    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA

    2 shared publications
  • Cristina P. Rodriguez

    Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA

    2 shared publications
  • George E. Laramore

    Department of Radiation Oncology, University of Washington, Seattle, Washington, USA

    2 shared publications
  • Jay Justin Liao

    Department of Radiation Oncology, University of Washington, Seattle, Washington, USA

    2 shared publications

Latest Publications

  • Exploring G‐Tube Timing and Clinical Outcomes in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Chemoradiation

    by Cameron Chalker, Jason C. Burton, Andy Kaempf, Jeong Youn Lim, Sarah Lowry, Erynn A. Beeson, Katherine Bagwell, Timur Mitin, Chetan V. Vakkalagadda, Jeremy Cetnar, et al.

    Background: G‐tube placement timing remains poorly characterized in patients with localized head and neck cancer (HNSCC) undergoing definitive chemoradiation (dCRT). Methods: We retrospectively analyzed 144 patients with HNSCC who received dCRT (2019–2024), categorized by “upfront” or “as‐needed” G‐tube strategy, to explore factors associated with timing and outcomes using propensity score weighting. Results: Most patients were White (85%) and male (83%); median age was 63 years. Upfront G‐tube placement occurred in 60 patients (42%) and was more common among women (64% vs. 37%, p = 0.015) and those with dysphagia (55% vs. 28%, p = 0.001) or receiving induction chemotherapy (71% vs. 38%, p = 0.023). dCRT duration, weight loss, ED visits, hospitalizations, ICU admissions, and survival did not differ. Upfront placement was associated with lower odds of chemotherapy modification (73% lower, p = 0.007) and fewer infusion clinic visits (average 3 fewer, p = 0.038). Conclusion: These findings suggest multiple factors influence G‐tube timing and outcomes, warranting prospective validation.

  • Open Access

    Baseline Hematological Parameters and Outcomes in Patients With Prostate Cancer Treated With Lu-177 PSMA Radioligand Therapy (RLT): A Multicenter Real-World Analysis

    by Colin P. Bergstrom, Cameron Chalker, Joseph Allen, Hong Song, Burcak Yilmaz, Alexandra Sokolova, Ali Raza Khaki

  • Open Access

    Use of PSMA PET/CT to detect prostate cancer metastatic to a preexisting thyroid nodule

    by Cameron Chalker, Burçak Yilmaz, Kristin Trone, Genevieve Parecki, Athena Chen, James Y. Lim, Nadine Mallak, Alexandra O. Sokolova

    Prostate cancer (PCa) seldom metastasizes to the thyroid gland, and only a limited number of cases are documented in the literature. The application of a relatively recent and highly sensitive imaging technique, prostate-specific membrane antigen (PSMA) positron emission tomography—computed tomography (PET/CT), has enhanced the identification of metastatic disease. Nevertheless, as PSMA is expressed in various tissue types, the clinical importance of a PSMA-avid thyroid lesion remains largely uncertain. A minor, yet noteworthy, percentage of these lesions are ultimately determined to be malignant. Here we describe the case of a 70-year-old man with a past medical history of Lynch syndrome who presented to an outpatient oncologic clinic for management of very high risk localized PCa. He developed metastatic recurrence and his disease progressed through several lines of therapy, including immunotherapy and targeted treatments. He was found to have a new, intense PSMA uptake in an existing, previously benign thyroid nodule. Sonographic evaluation revealed changing morphology despite grossly stable size. Repeat biopsy confirmed the unusual finding of PCa metastasis to a known thyroid nodule. The shift in PSMA avidity played a pivotal role in discerning this metastatic deposit. There is a potential risk that such lesions may be inadequately acknowledged. The impact of the patient’s Lynch syndrome on this presentation remains uncertain.


  • High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors

    by Cameron Chalker, Rafael Santana-Davila, Jenna M. Voutsinas, Qian (Vicky) Wu, Victoria Hwang, Christina S. Baik, Sylvia Lee, Brittany Barber, Neal D. Futran, Jeffrey J. Houlton, et al.

    Background/Objective: End-of-life health care utilization (EOLHCU) is largely uncharacterized among patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC), particularly now that immune checkpoint inhibitors (ICI) have been introduced to the treatment landscape. We examined this in a single-institution, retrospective study. Design/Settings: We utilized a database of deceased, ICI-treated RMHNSCC patients to obtain demographic and EOLHCU data, the latter of which included advanced care plan documentation (ACPD) and systemic therapy or emergency room (ER)/hospital/intensive care unit (ICU) admission within 30 days of death (DOD). This was compared with a cohort of deceased thoracic malignancy (TM) patients in an exploratory analysis. Multivariate analysis was performed to examine for association between patient factors (such as age, Eastern Cooperative Oncology Group (ECOG) performance status, or smoking status) and overall survival (OS); associations between the said patient factors and EOLHCU were also evaluated. This study was conducted at an academic, tertiary center in the United States. Results: The RMHNSCC patients ( n = 74) were more likely to have ACPD ( p < 0.01), an emergency department visit ( p < 0.01), and/or hospital admission ( p < 0.01) within 30 DOD relative to the TM group. There was no difference in ICU admissions, ICU deaths, or systemic therapy at end of life (EOL). The OS declined in association with ECOG performance status (PS) and smoking. No association was observed between patient factors and any EOLHCU metric. Conclusions: At our center, patients with ICI-treated RMHNSCC have higher rates of both ACPD and EOLHCU, suggesting high symptom burden and representing opportunities for further study into supportive care augmentation.

  • Open Access

    Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

    by Cameron Chalker, Jenna M. Voutsinas, Qian Vicky Wu, Rafael Santana‐Davila, Victoria Hwang, Christina S. Baik, Sylvia Lee, Brittany Barber, Neal D. Futran, Jeffrey J. Houlton, et al.

    Background: Anti‐PD1 checkpoint inhibitors (ICI) represent an established standard‐of‐care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this population is therefore unknown.Methods: We retrospectively reviewed RMHNSCC patients who received 1+ dose of ICI at our institution between 2013 and 2019. Demographic and clinical data were obtained; the latter included objective response (ORR), toxicity, and any unplanned hospitalization (UH). Associations were explored using uni‐ and multivariate analysis. Overall survival (OS) was estimated using a Cox proportional hazards model; ORR, toxicity, and UH were evaluated with logistic regression.Results: Of the 152 patients, 29 (19%) had an ECOG PS ≥2. Sixty‐six (44%) experienced toxicity; 54 (36%) had a UH. A multivariate model for OS containing PS, smoking status, and HPV status demonstrated a strong association between ECOG ≥2 and shorter OS (p < 0.001; HR = 3.30, CI = 2.01–5.41). An association between OS and former (vs. never) smoking was also seen (p < 0.001; HR = 2.17, CI = 1.41–3.35); current smoking did not reach statistical significance. On univariate analysis, poor PS was associated with inferior ORR (p = 0.03; OR = 0.25, CI = 0.06–0.77) and increased UH (p = 0.04; OR = 2.43, CI = 1.05—5.71). There was no significant association between toxicity and any patient characteristic.Conclusions: We observed inferior OS, ORR, and rates of UH among ICI‐treated RMHNSCC patients with ECOG 2/3. Our findings help frame discussion of therapeutic options in this poor‐risk population.


  • Efficacy of low-dose and/or adjuvant methadone in palliative medicine

    by Cameron Chalker, Hannah O'NEill, Faith Cranfield

    Objectives To summarise the current body of published evidence on the use of low-dose and/or adjuvant methadone in the palliative care setting. Methods The authors searched multiple databases (PubMED, SCORPUS, EMBASE and the Cochrane library) for relevant articles using the terms ‘methadone’, ‘palliative’, ‘low dose’ and ‘adjuvant’. The review was restricted to articles published between 2003 and 2018. Paediatric and single-case studies were also excluded. Evidence quality was assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) method. Results Our search yielded 171 results, of which seven met the inclusion criteria. Four were retrospective chart reviews, one was a retrospective cohort study, one was a case series and one was a double-blind randomised control trial. The overall quality was found to be very low. Of the seven articles, all seven reported some improvement in pain with the addition of low-dose or adjuvant methadone. This improvement was statistically significant in four out of seven articles; statistical significance was not commented on in the remaining three articles. Conclusion While case series and chart reviews offer promising results about the utility of adjuvant and/or low-dose methadone in the management of complex pain, the very low evidence quality, relative dearth of studies and near absence of randomised controlled trials make it impossible to draw firm conclusions. Thus, while very preliminary evidence suggests methadone is a potentially effective and valuable agent, further research must be performed before such findings can be implemented into clinical practice.